


## PHARMACEUTICAL 2018



## PUMA BIOTECHNOLOGY INC. Rank 294 of 342





## PHARMACEUTICAL 2018



## PUMA BIOTECHNOLOGY INC. Rank 294 of 342

The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 61% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is -144%, being 190% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	106,394
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	58,340
Liabilities, Non-Current	0
Other Assets	54,661
Other Compr. Net Income	13
Other Expenses	5,572
Other Liabilities	53,883
Other Net Income	435
Other Revenues	27,685
Property and Equipment	4,470
Research and Development	207,810
Selling, General and Administrative Expense	106,693

Output Variable	Value in 1000 USD
Assets	165,525
Liabilities	112,223
Expenses	320,075
Revenues	27,685
Stockholders Equity	53,302
Net Income	-291,955
Comprehensive Net Income	-291,948
Economic Capital Ratio	-144%

